GlassScriptPhysician profile
Jerad Scott Wagner
NPI 1932448347
$4,294.05
in general payments reported to CMS, 2019-2025
30 companies · $545 in 2025
The $545 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $756 · 2022: $1,251 · 2023: $913 · 2024: $829 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $619.93 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $532.70 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $512.83 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $457.76 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $425.02 | 2021-2023 | |
| Novo Nordisk INC | $386.51 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $278.19 | 2021-2025 | |
| Insulet Corporation | $249.15 | 2022-2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.98 | 2021-2023 | Jardiance |
| Xeris Pharmaceuticals, INC. | $112.59 | 2021-2024 | Keveyis, Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $67.99 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $62.14 | 2021-2024 | Prolia, Evenity, Otezla |
| Pfizer INC. | $51.54 | 2022-2024 | |
| Antares Pharma, INC. | $38.86 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Sumitomo Pharma America, INC. | $36.31 | 2024 | Gemtesa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $35.88 | 2023 | |
| Abbott Laboratories | $35.78 | 2023-2024 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $33.52 | 2021-2024 | Yupelri |
| Exact Sciences Corporation | $28.72 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $27.90 | 2023 | Ajovy, Austedo |
| Janssen Pharmaceuticals, INC | $26.09 | 2021-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $20.12 | 2024 | Trintellix |
| Astellas Pharma US INC | $17.63 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.55 | 2023 | Xifaxan |
| Nabriva Therapeutics, Plc | $15.03 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.49 | 2024 | Voquezna |
| Genentech USA, INC. | $14.46 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.00 | 2024 | Quviviq |
| Dexcom, INC. | $12.83 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerad Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.